EQUIPO DE FOTOTERAPIA CLINICA
Fototerapia de Pies - ¡NUEVO!
productos relacionados
Lamparas/Focos del Repuesto
Medidores 
Proteccion Para Ojos
Tratamiento de acne TRU-BLU
FOTOTERAPIA EN PRACTICAA
Sayuda para Sus Pacientes
Fototerapia vs Biologicos
Estudio de Psoralen y UVA
Estudio de vitiligo
Preguntas Frecuentes de Doctores
DESCUENTOS PARA DOCTORES
UNIDAD PARA paCientES EN CASA
Cabina Plegable del Hogar Foldalite
Tratamiento manual para manchas
Paneles de luz UVB en Casa
NOTICIAS
Productos nuevos para el pais
Próximas ferias comerciales
EXPERTOS EN FOTOTERAPIA
Escuche De Nuestros Consumidores
Acerca National Biological
¿Necesita ayuda?
Mapa del Sitio
Contactenos
800-338-5045


PATIENTS     PHYSICIANS     THIRD PARTY PAYERS     HOME    

Randomized Double Blind Trial of Treatment of Vitiligo
     Efficacy of Psoralen-UVA Therapy vs Narrowband UVB Therapy

Randomized Double Blind Trial of Treatment of Vitiligo: Efficacy of Psoralen-UVA Therapy vs Narrowband UVB Therapy. Yones SS, Der D, Palmer RA, Garibaldinos TM, Hawk JLM. Arch Dermatol 2007; 143:578-84.                                           Read Full Article
OBJECTIVE: To compare the efficacy of oral psoralen- UV-A (PUVA) with that of narrowband- UV-B (NB-UVB) phototherapy in patients with nonsegmental vitiligo.
DESIGN: Double-blind randomized study.
SETTING: Phototherapy unit in a university hospital.
PATIENTS:
Fifty-six patients with nonsegmental vitiligo.
INTERVENTIONS: 
Twice-weekly therapy with PUVA or NB-UVB.
MAIN OUTCOME MEASURES:
The change in body surface area affected by vitiligo and the color match of repigmented skin compared with unaffected skin were assessed after 48 sessions of therapy, at the end of the therapy course, and 12 months after the end of therapy.
RESULTS: 
The results in the 25 patients each in the PUVA and NB-UVB groups who began therapy were analyzed.  The median number of treatments was 47 in the PUVA-treated group and 97 in the NB-UVB group (P=.03); we suspect this difference was because of differences in efficacy and adverse effects between the two modalities, such that patients in the NB-UVB group wanted a longer course of treatment. At the end of therapy, 16 (64%) of 25 patients in the NB-UVB group showed greater than 50% improvement in body surface area affected compared with 9 (36%) of 25 patients in the PUVA group. The color match of repigmented skin was excellent in all patients in the NB-UVB group but in only 11 (44%) of those in the PUVA group (P<.001). In patients who completed 48 sessions, the improvement in body surface area affected by vitiligo was greater with NB-UVB therapy than with PUVA therapy (P<.007). Twelve months after the cessation of therapy, the superiority of NB-UVB tended to be maintained.
CONCLUSIONS
In the treatment of nonsegmental vitiligo, NB-UVB therapy is superior to oral PUVA therapy.

Read Full Article